ＳＴＩ5 71是人工合成的酪氨酸激酶抑制物 ,可以通过竞争性抑制酪氨酸激酶ＡＴＰ结合位点发挥作用 ,抑制酪氨酸磷酸化 ,使表达ｂｃｒ ａｂｌ的造血细胞停止生长或凋亡。临床前期试验已证明ＳＴＩ5 71的抗白血病活性 ,在此基础上 ,选择经α 干扰素治疗失败ＣＭＬ患者进行ＳＴＩ5 STI571 is a synthetic tyrosine kinase inhibitor that inhibits tyrosine phosphorylation and stops growth or apoptosis of hematopoietic cells that express bcr abl by competitively inhibiting the ATP binding site of tyrosine kinase. Preclinical trials have demonstrated the anti-leukemic activity of STI5 71, on the basis of which STI5 patients were selected for failure of treatment with interferon alpha